nach oben

Current Gastroenterology Reports

Erschienen in:

01.06.2011

Ablative Therapies for Barrett’s Esophagus

verfasst von: Katherine S. Garman, Nicholas J. Shaheen

Erschienen in: Current Gastroenterology Reports | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Barrett’s esophagus has gained increased clinical attention because of its association with esophageal adenocarcinoma, a cancer with increasing incidence and poor survival rates. The goals of ablating Barrett’s esophagus are to decrease esophageal cancer rates and to improve overall survival and quality of life. Different techniques have been developed and tested for their effectiveness eradicating Barrett’s epithelium. This review assesses the literature associated with different ablative techniques. The safety and efficacy of different techniques are discussed. This review concludes with recommendations for the clinician, including specific strategies for patient care decisions for patients with Barrett’s esophagus with varying degrees of dysplasia.

Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB. Temporal trends (1973–1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol. 2003;98:1627–33.PubMed

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRef

Polednak AP. Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. Int J Cancer. 2003;105:98–100.PubMedCrossRef

Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100:1184–7.PubMedCrossRef

Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670–7.PubMedCrossRef

Hayeck TJ, Kong CY, Spechler SJ, et al. The prevalence of Barrett's esophagus in the US: estimates from a simulation model confirmed by SEER data. Dis Esophagus. 2010;23:451–7.PubMedCrossRef

Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology. 2000;119:333–8.PubMedCrossRef

Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8:235–44. quiz e32.PubMedCrossRef

• Shaheen NJ, Sharma P, Overholt BF, et al.: Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009;360:2277–88. This randomized clinical trial evaluated radiofrequency ablation in patients with dysplastic BE. PubMedCrossRef

10.

Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005;62:488–98.PubMedCrossRef

11.

Konda VJ, Ross AS, Ferguson MK, et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? Clin Gastroenterol Hepatol. 2008;6:159–64.PubMedCrossRef

12.

Crockett SD, Lippmann QK, Dellon ES, Shaheen NJ. Health-related quality of life in patients with Barrett's esophagus: a systematic review. Clin Gastroenterol Hepatol. 2009;7:613–23.PubMedCrossRef

13.

• Shaheen NJ, Peery AF, Hawes RH, et al.: Quality of life following radiofrequency ablation of dysplastic Barrett's esophagus. Endoscopy 2010;42:790–9. This article is one of the few reports of quality of life in patients with BE who undergo ablation. PubMedCrossRef

14.

Prasad GA, Wang KK, Buttar NS, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology. 2007;132:1226–33.PubMedCrossRef

15.

Inadomi JM, Somsouk M, Madanick RD, et al. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology. 2009;136:2101–14. e1-6.PubMedCrossRef

16.

Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105:1523–30.PubMedCrossRef

17.

Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368–78.PubMedCrossRef

18.

Ajumobi A, Bahjri K, Jackson C, Griffin R. Surveillance in Barrett's esophagus: an audit of practice. Dig Dis Sci. 2010;55:1615–21.PubMedCrossRef

19.

Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008;103:788–97.PubMedCrossRef

20.

Lichtenstein DR, Cash BD, Davila R, et al. Role of endoscopy in the management of GERD. Gastrointest Endosc. 2007;66:219–24.PubMedCrossRef

21.

Fleischer DE, Odze R, Overholt BF, et al. The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett's esophagus. Dig Dis Sci. 2010;55:1918–31.PubMedCrossRef

22.

Falk GW. Radiofrequency ablation of Barrett's esophagus: let's not get ahead of ourselves. Dig Dis Sci. 2010;55:1811–4.PubMedCrossRef

23.

Rees JR, Lao-Sirieix P, Wong A, Fitzgerald RC: Treatment for Barrett's oesophagus. Cochrane Database Syst Rev 2010:CD004060.

24.

Sampliner RE, Fennerty B, Garewal HS. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc. 1996;44:532–5.PubMedCrossRef

25.

Sampliner RE, Faigel D, Fennerty MB, et al. Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study. Gastrointest Endosc. 2001;53:554–8.PubMedCrossRef

26.

Sharma P, Bhattacharyya A, Garewal HS, Sampliner RE. Durability of new squamous epithelium after endoscopic reversal of Barrett's esophagus. Gastrointest Endosc. 1999;50:159–64.PubMedCrossRef

27.

Dulai GS, Jensen DM, Cortina G, et al. Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett's esophagus. Gastrointest Endosc. 2005;61:232–40.PubMedCrossRef

28.

Sharma P, Wani S, Weston AP, et al. A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results. Gut. 2006;55:1233–9.PubMedCrossRef

29.

Bright T, Watson DI, Tam W, et al. Randomized trial of argon plasma coagulation versus endoscopic surveillance for barrett esophagus after antireflux surgery: late results. Ann Surg. 2007;246:1016–20.PubMedCrossRef

30.

Dulai GS, Guha S, Kahn KL, et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122:26–33.PubMedCrossRef

31.

Chennat J, Konda VJ, Ross AS, et al. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma–an American single-center experience. Am J Gastroenterol. 2009;104:2684–92.PubMedCrossRef

32.

Ackroyd R, Brown NJ, Davis MF, et al. Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial. Gut. 2000;47:612–7.PubMedCrossRef

33.

Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc. 2007;66:460–8.PubMedCrossRef

34.

Badreddine RJ, Prasad GA, Wang KK, et al. Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus. Gastrointest Endosc. 2010;71:697–703.PubMedCrossRef

35.

Hage M, Siersema PD, van Dekken H, et al. 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial. Gut. 2004;53:785–90.PubMedCrossRef

36.

Kelty CJ, Ackroyd R, Brown NJ, et al. Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther. 2004;20:1289–96.PubMedCrossRef

37.

Sharma VK, Wang KK, Overholt BF, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc. 2007;65:185–95.PubMedCrossRef

38.

Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc. 2008;68:867–76.PubMedCrossRef

39.

• Fleischer DE, Overholt BF, Sharma VK, et al.: Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy 2010;42:781–9. This study presents some of the longest follow-up data regarding ablation of nondysplastic BE as presented in the AIM-II study. PubMedCrossRef

40.

Roorda AK, Marcus SN, Triadafilopoulos G. Early experience with radiofrequency energy ablation therapy for Barrett's esophagus with and without dysplasia. Dis Esophagus. 2007;20:516–22.PubMedCrossRef

41.

Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Stepwise circumferential and focal ablation of Barrett's esophagus with high-grade dysplasia: results of the first prospective series of 11 patients. Endoscopy. 2008;40:359–69.PubMedCrossRef

42.

Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy. 2008;40:370–9.PubMedCrossRef

43.

Sharma VK, Kim HJ, Das A, et al. A prospective pilot trial of ablation of Barrett's esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system). Endoscopy. 2008;40:380–7.PubMedCrossRef

44.

Hernandez JC, Reicher S, Chung D, et al. Pilot series of radiofrequency ablation of Barrett's esophagus with or without neoplasia. Endoscopy. 2008;40:388–92.PubMedCrossRef

45.

Sharma VK. Jae Kim H, Das A, et al.: Circumferential and focal ablation of Barrett's esophagus containing dysplasia. Am J Gastroenterol. 2009;104:310–7.PubMedCrossRef

46.

Ganz RA, Overholt BF, Sharma VK, et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc. 2008;68:35–40.PubMedCrossRef

47.

Pouw RE, Wirths K, Eisendrath P, et al. Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol. 2010;8:23–9.PubMedCrossRef

48.

Velanovich V. Endoscopic endoluminal radiofrequency ablation of Barrett's esophagus: initial results and lessons learned. Surg Endosc. 2009;23:2175–80.PubMedCrossRef

49.

Vassiliou MC, von Renteln D, Wiener DC, et al. Treatment of ultralong-segment Barrett's using focal and balloon-based radiofrequency ablation. Surg Endosc. 2010;24:786–91.PubMedCrossRef

50.

Johnston MH, Eastone JA, Horwhat JD, et al. Cryoablation of Barrett's esophagus: a pilot study. Gastrointest Endosc. 2005;62:842–8.PubMedCrossRef

51.

Dumot JA, Vargo 2nd JJ, Falk GW, et al. An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc. 2009;70:635–44.PubMedCrossRef

52.

Larghi A, Lightdale CJ, Memeo L, et al. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus. Gastrointest Endosc. 2005;62:16–23.PubMedCrossRef

53.

Chennat J, Konda VJ, Hart J, et al.: Complete Barrett's eradication endoscopic mucosal resection (CBE-EMR): long-term results of management of high grade dysplasia (HGD) and intramucosal carcinoma (IMC). In: Digestive Disease Week; 2010 May 2010; 2010. p. S1517.

54.

• Pouw RE, Seewald S, Gondrie JJ, et al.: Stepwise radical endoscopic resection for eradication of Barrett's oesophagus with early neoplasia in a cohort of 169 patients. Gut 2010;59:1169–77. This is one of the largest studies of endoscopic mucosal resection as a strategy for ablation of BE. PubMedCrossRef

55.

Van Vilsteren FG, Pouw RE, Seewald S, et al. A multi-center randomized trial comparing stepwise radical endoscopic resection versus radiofrequency ablation for Barrett esophagus containing high-grade dysplasia and/or early cancer, Abstract 939. Gastrointest Endosc. 2009;69:AB133–4.CrossRef

56.

Eldaif SM, Lin E, Singh KA, et al. Radiofrequency ablation of Barrett's esophagus: short-term results. Ann Thorac Surg. 2009;87:405–10. discussion 10–1.PubMedCrossRef

57.

• Shaheen NJ, Greenwald BD, Peery AF, et al.: Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 2010;71:680–5. This study represents one of the largest reports of cryotherapy for ablation of BE. PubMedCrossRef

Titel: Ablative Therapies for Barrett’s Esophagus
verfasst von: Katherine S. Garman
Nicholas J. Shaheen
Publikationsdatum: 01.06.2011
Verlag: Current Science Inc.
Erschienen in: Current Gastroenterology Reports / Ausgabe 3/2011
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI: https://doi.org/10.1007/s11894-011-0182-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Intestinal Obstruction Syndromes in Cystic Fibrosis: Meconium Ileus, Distal Intestinal Obstruction Syndrome, and Constipation

Obesity and GERD: Pathophysiology and Effect of Bariatric Surgery

Surgery for Portal Hypertension in Children

Recent Progress in Congenital Diarrheal Disorders

Exploring the Differential Diagnosis of Joint Complaints in Pediatric Patients with Inflammatory Bowel Disease